Screen, Select, Enhance: A joint evitria AG – Biofidus workflow for ADCC‑enhanced antibody development
We collaborated with evitria AG on an integrated workflow that connects evitria’s high‑throughput antibody expression and selection pipeline with mechanistic validation for ADCC‑enhanced candidates. The poster, authored by Julia Pizzolato (evitria AG) with contributions from our colleagues Julian Wichmann and Tobias Luttermann, reports that evitria’s in-licensed GlymaxX‑mediated afucosylated antibody technology selectively increase FcγRIIIa binding (including […]
A holistic analysis platform for assessing protein modification and functional activity
Linking Protein Modifications to Functional Impact. Protein modifications are critical for the efficacy, safety, and stability of therapeutic antibodies. Here, we introduce a comprehensive analysis platform tailored to assess post-translational modifications of therapeutic proteins hand in hand with their functional activity. In the present approach, we successfully applied peptide mapping with LC-ESI-MS to determine deamidation […]